Pancreatic Cancer Research

ResearcherYokohama City University HospitalActive in the last 2 years

Noritoshi Kobayashi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9181-3722; OpenAlex author ID A5061777118. Sources: OpenAlex.

Their work

Papers
20 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
62
Papers, trials and grants by year

2011: 3 papers · 2012: none · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: 2 papers · 2025: 3 papers · 2026: 1 paper

Papers 20

  1. Enhancing the Diagnostic Performance of Repeated Endoscopic Ultrasound-Guided Tissue Acquisition Combined with Surrogate Repeated Endoscopic Retrograde Pancrea… Co-author DOI 10.1007/s10620-025-09373-5↗
  2. Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of trea… Co-author DOI 10.1007/s00535-024-02186-9↗
  3. Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probabi… Co-author DOI 10.1007/s00535-025-02215-1↗
  4. Treatment of initially unresectable local advanced pancreatic adenocarcinoma with FOLFIRINOX: A prospective study YCOG1403 (C-FLAP study). Co-author DOI 10.1038/s41598-025-23608-5↗
  5. First-line Chemotherapy in Combination With Oral Recombinant Methioninase and a Low-methionine Diet for a Stage IV Inoperable Pancreatic-Cancer Patient Resulte… Co-author DOI 10.21873/anticanres.17215↗
  6. Diagnostic Value of Contrast-Enhanced Dual-Energy Computed Tomography in the Pancreatic Parenchymal and Delayed Phases for Pancreatic Cancer. Co-author DOI 10.3390/tomography10100117↗
  7. A Case of BRCA2-Pathogenic Variant Breast Cancer With Metachronous Endometrial Cancer and Pancreatic Cancer. Co-author DOI 10.14740/wjon1658↗
  8. FOLFIRINOX in Pancreatic Cancer: Risk Factors for Febrile Neutropenia and Severe Neutropenia - Nationwide Study Analysis. Co-author DOI 10.21873/anticanres.16601↗
  9. Covered metallic stent placement for biliary drainage could be promising in the coming era of neoadjuvant chemo-radiation therapy for all pancreatic cancer. Co-author DOI 10.1002/jhbp.958↗
  10. FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan. Co-author DOI 10.1016/j.pan.2020.07.006↗
  11. Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy. First author DOI 10.1016/j.pan.2018.11.001↗
  12. Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX. Co-author DOI 10.1111/cas.13883↗
  13. Influence of initial dose intensity on efficacy of FOLFIRINOX in patients with advanced pancreatic cancer. Co-author DOI 10.18632/oncotarget.26633↗
  14. Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan. Co-author DOI 10.1097/mpa.0000000000001049↗
  15. Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure. Co-author DOI 10.1097/md.0000000000006769↗
  16. [A case of post-operative recurrence of pancreatic cancer in the residual pancreas treated by resection of the residual pancreas following radiological complet… Co-author PMID 25131881↗
  17. Collapsin response mediator protein 4 expression is associated with liver metastasis and poor survival in pancreatic cancer. Co-author DOI 10.1245/s10434-012-2491-3↗
  18. Usefulness of endoscopic biopsy using FOXP3+ Treg up-regulation in the duodenal papilla in the differential diagnosis between autoimmune pancreatitis and pancr… Co-author DOI 10.1007/s00534-010-0359-0↗
  19. Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer. Co-author DOI 10.1111/j.1349-7006.2011.02053.x↗
  20. Covered stent placement for duodenal obstruction in pancreatic cancer. Co-author DOI 10.1159/000313695↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Itaru Endo · 10 shared papers, 2011–2026 · strength 1.24
  2. Yasushi Ichikawa · 8 shared papers, 2013–2025 · strength 1.05
  3. Kensuke Kubota · 9 shared papers, 2011–2026 · strength 0.97
  4. Satoshi Kobayashi · 7 shared papers, 2018–2025 · strength 0.78
  5. Naohiro Okano · 6 shared papers, 2018–2025 · strength 0.70
  6. Yusuke Kurita · 4 shared papers, 2019–2026 · strength 0.66
  7. Sho Hasegawa · 3 shared papers, 2021–2026 · strength 0.56
  8. Atsushi Nakajima · 6 shared papers, 2011–2024 · strength 0.49
  9. Nobumasa Mizuno · 5 shared papers, 2018–2023 · strength 0.46
  10. Masato Ozaka · 5 shared papers, 2018–2023 · strength 0.46
  11. Akiko Todaka · 5 shared papers, 2018–2023 · strength 0.46
  12. Atsushi Nakajima · 2 shared papers, 2024–2026 · strength 0.43
  13. Satoshi Fujii · 2 shared papers, 2023–2026 · strength 0.43
  14. Makoto Ueno · 3 shared papers, 2019–2025 · strength 0.41
  15. Kentaro Sudo · 4 shared papers, 2018–2023 · strength 0.37
  16. Keiko Kamei · 4 shared papers, 2018–2023 · strength 0.37
  17. Hideyuki Hayashi · 4 shared papers, 2018–2023 · strength 0.37
  18. Shin Yagi · 2 shared papers, 2021–2026 · strength 0.37
  19. Akinori Asagi · 2 shared papers, 2025 · strength 0.32
  20. Yohei Kitano · 2 shared papers, 2025 · strength 0.32
  21. Nana Kimura · 2 shared papers, 2025 · strength 0.32
  22. Kunihiro Tsuji · 2 shared papers, 2025 · strength 0.32
  23. Kumiko Umemoto · 2 shared papers, 2025 · strength 0.32
  24. Takeshi Terashima · 2 shared papers, 2025 · strength 0.32
  25. Masayuki Ueno · 2 shared papers, 2025 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.